MEEDER ASSET MANAGEMENT INC - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 556 filers reported holding BIO-TECHNE CORP in Q3 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
MEEDER ASSET MANAGEMENT INC ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$159,012
-16.6%
2,3360.0%0.01%
-7.1%
Q2 2023$190,688
+10.0%
2,3360.0%0.01%0.0%
Q1 2023$173,308
+48.1%
2,336
+467.0%
0.01%
+100.0%
Q3 2022$117,000
-44.0%
412
-31.9%
0.01%
-41.7%
Q2 2022$209,000
-52.6%
605
-40.7%
0.01%
-45.5%
Q1 2022$441,000
+103.2%
1,020
+143.4%
0.02%0.0%
Q4 2021$217,000
-62.3%
419
-64.7%
0.02%
-26.7%
Q3 2021$575,000
+9.1%
1,188
+1.5%
0.03%
+20.0%
Q2 2021$527,000
+7.8%
1,170
-8.7%
0.02%0.0%
Q1 2021$489,000
+3975.0%
1,281
+3271.1%
0.02%
+733.3%
Q4 2020$12,000
-94.8%
38
-95.9%
0.00%
-80.0%
Q3 2020$230,000
+45.6%
930
+55.3%
0.02%
+50.0%
Q2 2020$158,000
+203.8%
599
+119.4%
0.01%
+150.0%
Q1 2020$52,000
-8.8%
273
+3.8%
0.00%
+33.3%
Q4 2019$57,000
+9.6%
263
-1.9%
0.00%0.0%
Q3 2019$52,000
-78.9%
268
-77.3%
0.00%
-82.4%
Q2 2019$247,000
+6.0%
1,1810.0%0.02%
-5.6%
Q1 2019$233,000
+37.1%
1,1810.0%0.02%
+20.0%
Q4 2018$170,000
+17.2%
1,181
+66.1%
0.02%
+36.4%
Q3 2018$145,000
-99.6%
711
+220.3%
0.01%
+266.7%
Q2 2018$32,845,000
+20300.6%
222
-87.6%
0.00%
-80.0%
Q4 2015$161,0001,7860.02%
Other shareholders
BIO-TECHNE CORP shareholders Q3 2021
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 275,000$18,719,25020.14%
Montanaro Asset Management Ltd 408,800$27,827,0164.90%
Sandhill Capital Partners LLC 613,061$41,731,0913.90%
Pembroke Management, LTD 365,611$24,887,1413.40%
DF DENT & CO INC 3,349,047$227,969,6483.34%
Brown Capital Management 3,158,004$214,965,3323.30%
Ownership Capital B.V. 1,786,273$121,591,6033.05%
STONE RUN CAPITAL, LLC 86,335$5,876,8232.88%
Jackson Square Partners, LLC 1,260,547$85,805,4342.87%
Summit Creek Advisors LLC 284,681$19,378,2362.64%
View complete list of BIO-TECHNE CORP shareholders